Zepbound\u00ae is tirzepatide approved for chronic weight management at doses from 2.5 mg up to 15 mg weekly. It’s the same molecule as Mounjaro\u00ae, with a different label and indication. The phase 3 trial is SURMOUNT-1 (Jastreboff et al. 2022 NEJM), which produced 20.9% mean body weight loss at 72 weeks on the 15 mg dose.<\/p>\n
That’s the strongest published mean loss from any GLP-1 trial to date. SURMOUNT-5 (Aronne et al. 2025 NEJM) ran tirzepatide head-to-head against semaglutide and found tirzepatide produced 20.2% vs semaglutide’s 13.7% at 72 weeks.<\/p>\n
This article walks through the Zepbound week-by-week curve from the start of dose escalation through the SURMOUNT-1 endpoint at week 72. The trial data is the cleanest reference point for what to expect on standard titration.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Zepbound titration starts at 2.5 mg weekly for 4 weeks, moves to 5 mg for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated.<\/strong> Maintenance options are 5, 10, or 15 mg.<\/p>\n Quick Answer: SURMOUNT-1 (Jastreboff et al. 2022 NEJM): 20.9% mean loss at 72 weeks on 15 mg<\/p>\n The 2.5 mg dose is a tolerance starter. It’s not officially a maintenance dose but it still produces noticeable appetite suppression for most patients within the first 1-2 weeks.<\/p>\n Maintenance doses scale with weight loss outcomes in SURMOUNT-1: 5 mg produced 15% mean loss, 10 mg produced 19.5%, and 15 mg produced 20.9% at 72 weeks. Higher dose, better mean outcome, more side effects for some.<\/p>\n Many patients can reach 10 or 15 mg without trouble. Others stall at 7.5 mg because of GI tolerance. Lower maintenance doses still produce significant weight loss compared to placebo.<\/p>\n Mean weight loss by week 4 in SURMOUNT-1 was 2-3% of starting body weight.<\/strong> For a 240 lb starting weight, that’s 5-7 lb.<\/p>\n The 2.5 mg dose produces clear appetite changes in most patients within the first 7-10 days. Cravings decrease, portion sizes drop without conscious effort, and satiety hits earlier.<\/p>\n Side effects in this window are typically mild. Nausea is most common, peaking in the first week. Constipation affects a meaningful share of patients and is worth addressing early with hydration and fiber.<\/p>\n Tirzepatide’s dual GIP\/GLP-1 mechanism produces stronger early appetite effects than pure GLP-1 drugs at equivalent starting doses, which is why the 2.5 mg starter often produces clearer behavior changes than semaglutide’s 0.25 mg starter.<\/p>\n By week 12, SURMOUNT-1 patients on the 15 mg arm averaged about 8-9% body weight loss.<\/strong> Patients still in titration had reached 7.5 mg by this point.<\/p>\n For a 240 lb starting weight, week 12 lands around 218-221 lb (19-22 lb down). For a 200 lb starting weight, week 12 lands around 182-184 lb (16-18 lb down).<\/p>\n The 5 mg and 7.5 mg doses produce strong appetite suppression. Calorie intake drops substantially without much conscious effort.<\/p>\n Each dose increase can flare side effects for 7-10 days, then settle. Patients who can’t tolerate an increase typically pause at the prior dose for an extra month rather than reverse.<\/p>\n This window is the highest-discontinuation window. Most Zepbound stops happen in the first 12 weeks because of side effects. Pushing through is the biggest determinant of long-term results.<\/p>\n Most patients reach 10 mg or 15 mg between weeks 16-24.<\/strong> By week 24, SURMOUNT-1 mean cumulative loss on 15 mg was around 14%.<\/p>\n Once on the target maintenance dose, weekly loss rate peaks. For most patients this is 1-3 lb per week. Some lose faster, some slower.<\/p>\n Body composition changes become clearly visible. Tape measurements at waist and hips often drop faster than scale weight implies because body fat is mobilizing.<\/p>\n This is the window where most patients see dramatic visible change. Clothes fit dramatically differently. Photos taken 3 months apart show clear differences.<\/p>\n Between weeks 24 and 40, SURMOUNT-1 patients on 15 mg moved from about 14% to about 18% cumulative loss.<\/strong> That’s the steepest part of the curve.<\/p>\n This is where body composition work matters most. Adding resistance training 2-3x per week preserves lean mass and supports metabolic rate during loss.<\/p>\n Adequate protein intake (1.2-1.6 g\/kg body weight) compounds the resistance training effect. Most patients fall short on protein without tracking. A 180 lb person targeting 1.4 g\/kg needs about 115 g protein per day.<\/p>\n Side effects typically stabilize by month 5-6. Most patients tolerate the target dose without ongoing GI issues by this point.<\/p>\n By week 52, SURMOUNT-1 cumulative loss was approaching 19% on the 15 mg arm.<\/strong> The slope from week 40 to week 52 is less steep than weeks 24 to 40.<\/p>\n Metabolic adaptation kicks in. Hunger adaptation partially offsets the drug effect. The residual deficit shrinks because the body is smaller.<\/p>\n Real-world patients sometimes notice plateaus in this window. Most aren’t true plateaus, they’re normal variation or behavior drift. Tracking food tightly for 4-6 weeks usually surfaces calorie creep.<\/p>\n True plateaus are 3+ consecutive weeks of no movement on a stable dose with consistent eating. Those typically don’t show up until weeks 50-60 for tirzepatide at full dose.<\/p>\n Key Takeaway: 36.2% of SURMOUNT-1 patients hit 25%+ loss on 15 mg at 72 weeks<\/p>\n SURMOUNT-1 ran 72 weeks and reported 20.9% mean cumulative loss at endpoint on 15 mg.<\/strong> The curve was still trending down at study close.<\/p>\n Top responders in SURMOUNT-1 hit 30%+ body weight loss by week 72. About 16% of patients on 15 mg crossed that threshold. The top quartile averaged above 28%.<\/p>\n For a 240 lb starting weight, the SURMOUNT-1 mean would land at about 190 lb at week 72. Top responders would be at 168-180 lb. Partial responders would be at 215-220 lb.<\/p>\n Continued treatment past 72 weeks produces another 2-3 percentage points of loss for adherent top-dose patients in months 18-24. Beyond that the curve flattens.<\/p>\n Extension data is limited but available from SURMOUNT-4 (Aronne et al.<\/strong> 2024 JAMA), which examined continued vs withdrawn tirzepatide. Patients who stayed on the drug at 36 weeks beyond the initial run-in continued to lose modest weight. Patients who switched to placebo regained substantial weight.<\/p>\n The maintenance phase plateau weight is the drug-defended weight. Continuing tirzepatide is what holds it. Stopping typically produces gradual regain over 12-18 months.<\/p>\n For patients past goal weight, the question becomes maintenance dose. Some stay at 15 mg long-term. Others step down to 10 mg or 5 mg for cost or side-effect reasons. Lower maintenance doses can produce gradual regain, so step-down requires monitoring.<\/p>\n Different molecules (tirzepatide vs semaglutide), different mechanisms (dual GIP\/GLP-1 vs pure GLP-1).<\/strong><\/p>\n SURMOUNT-5 ran the direct head-to-head and produced clear results. Tirzepatide outperformed semaglutide at every measured timepoint and at endpoint (20.2% vs 13.7% at 72 weeks).<\/p>\n The gap shows up early. By week 12, tirzepatide patients are typically 1-2 percentage points ahead. The gap widens through week 36 and holds through week 72.<\/p>\n For patients prioritizing maximum weight loss, Zepbound has the stronger published evidence. For patients with established cardiovascular disease, semaglutide has more outcomes data (SELECT trial).<\/p>\n Real-world patients commonly run 3-5 percentage points below the trial mean at any given week.<\/strong> The drivers are titration delays, missed doses, supply issues, and weaker lifestyle adherence.<\/p>\n If you’re at 6% loss by week 24 instead of 14%, you’re below average but still on a real trajectory. If you’re at 1-2% by week 24 on a stable dose, you’re a likely partial responder.<\/p>\n Early response is the cleanest predictor. 5%+ loss by week 12 strongly predicts being in the upper tier at week 72. Less than 2% by week 12 on appropriate dose suggests partial response and warrants a clinical conversation.<\/p>\n TrimRx offers compounded tirzepatide as part of a personalized treatment plan, and the free assessment quiz can map dose and approach to your situation. Patients who plateau or partial-respond often benefit from clinical review of dose, adherence, and lifestyle factors.<\/p>\n For top responders on 15 mg with weekly adherence, the 12-month realistic range is 25-30% body weight loss.<\/strong> The 18-month range pushes to 28-32% for the top decile.<\/p>\n The 30%+ club represents about 16% of patients in SURMOUNT-1 at week 72. That’s roughly 1 in 6 patients reaching what would historically require bariatric surgery.<\/p>\n The top end requires hitting 15 mg, weekly adherence (no missed doses for extended periods), and combining the drug with reasonable food and movement habits. Drug-only patients tend to land in the middle of the response distribution, not the top.<\/p>\n Body composition outcomes depend heavily on resistance training during the loss phase. Patients who add resistance work preserve more lean mass and end with better metabolic markers at the new weight.<\/p>\n Bottom line: SURMOUNT-OSA led to FDA approval of tirzepatide for obstructive sleep apnea in Dec 2024<\/p>\n SURMOUNT-1 patients averaged 2-3% loss by week 4 on 2.5 mg. For a 240 lb start, that’s 5-7 lb. Individual range is wide. Some lose 10+ lb in month 1, others lose 2-3 lb.<\/p>\n Around 14% on the 15 mg arm based on SURMOUNT-1 with most patients having titrated up by then. Lower doses produce proportionally less: 10% on 5 mg, 12% on 10 mg.<\/p>\n The 52-week SURMOUNT-1 number on 15 mg was approximately 18-19% mean cumulative loss. Top responders hit 25%+. Partial responders at the same dose hit 8-10%.<\/p>\n Yes. Same molecule (tirzepatide), same dosing, same expected curve. Different label (Zepbound is for chronic weight management, Mounjaro is for type 2 diabetes).<\/p>\n Yes. SURMOUNT-1 reported 15% mean loss on the 5 mg arm at 72 weeks, which is still substantial. Lower doses are reasonable maintenance options when higher doses produce intolerable side effects.<\/p>\n Sleeve gastrectomy produces about 25-30% total body weight loss at 1-2 years. Zepbound 15 mg in SURMOUNT-1 produced 20.9% at 72 weeks with the curve still moving. The gap is narrower than it was for prior obesity drugs.<\/p>\n Yes, very likely. SURMOUNT-4 (Aronne et al. 2024 JAMA) showed substantial regain after withdrawal. The drug-defended weight requires continued dosing to maintain.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Zepbound is tirzepatide approved for chronic weight management at doses from 2.5 mg up to 15 mg weekly.<\/p>\n","protected":false},"author":11,"featured_media":91102,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Zepbound Weight Loss by Week: Full Timeline","_yoast_wpseo_metadesc":"Zepbound is tirzepatide approved for chronic weight management at doses from 2.5 mg up to 15 mg weekly.","_yoast_wpseo_focuskw":"zepbound weight loss","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[14],"tags":[],"class_list":["post-91103","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zepbound"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=91103"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91103\/revisions"}],"predecessor-version":[{"id":92103,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91103\/revisions\/92103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/91102"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=91103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=91103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=91103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Weeks 1-4: What Happens on 2.5 Mg?<\/h2>\n
Weeks 5-12: Through the Early Dose Ramp<\/h2>\n
Weeks 13-24: Hitting Maintenance Dose<\/h2>\n
Weeks 24-40: The Peak Loss Zone<\/h2>\n
Weeks 40-52: Into the Steady Zone<\/h2>\n
Weeks 52-72: The SURMOUNT-1 Endpoint<\/h2>\n
What Happens Past 72 Weeks on Zepbound?<\/h2>\n
How Does Zepbound Compare to Wegovy\u00ae Week-by-week?<\/h2>\n
What If Your Timeline Is Slower Than SURMOUNT-1?<\/h2>\n
What’s the Realistic Top-end Zepbound Result?<\/h2>\n
FAQ<\/h2>\n
How Much Weight Will I Lose in the First Month on Zepbound?<\/h3>\n
What’s the Average Zepbound Weight Loss at 6 Months?<\/h3>\n
How Much Weight Loss Should I Expect at 1 Year on Zepbound?<\/h3>\n
Is Zepbound the Same as Mounjaro Week-by-week?<\/h3>\n
Can I Stay on 5 Mg Long-term If 15 Mg Is Too Rough?<\/h3>\n
How Does Zepbound Compare to Bariatric Surgery for Weight Loss?<\/h3>\n
Will I Regain Weight If I Stop Zepbound?<\/h3>\n